Results 151 to 160 of about 144,049 (286)

Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ...
Clémence Bertold   +6 more
wiley   +1 more source

Triggering Receptor Expressed on Myeloid Cells‐2 Regulates Innate Lymphoid Cell Levels in Bleomycin‐Induced Pulmonary Fibrosis

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Idiopathic pulmonary fibrosis, a pathological change causing poor outcomes, is not reversible despite current antifibrotic therapy. Emerging evidence suggests that innate lymphoid cells (ILCs) mediate lung inflammation and fibrosis after stimulation by endogenous factors.
Hsiao‐Chin Shen   +7 more
wiley   +1 more source

Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study

open access: yesThe Laryngoscope, EarlyView.
The impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms.
Ahmad Odeh   +12 more
wiley   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

open access: yesMicrobiota Medicine Research, EarlyView.
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai   +6 more
wiley   +1 more source

Evidence‐based guideline for clinical practice in the diagnosis, treatment, management, and prevention of recurrent wheezing in infants and toddlers in China

open access: yesPediatric Investigation, EarlyView.
ABSTRACT Wheezing is a common respiratory symptom in infants and toddlers, and recurrent wheezing is a significant respiratory disorder affecting this age group. Given the multifactorial etiology of recurrent wheezing, clinical practice lacks standardized diagnostic and therapeutic protocols. Recent years have witnessed substantial progress in clinical
Committee of Pediatrics   +16 more
wiley   +1 more source

Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients

open access: yesClinical and Translational Allergy
Lisa P. van derRijst   +6 more
doaj   +1 more source

The polysaccharide Pullulan improves the initial steps of allergen‐specific immunotherapy in dogs

open access: yesVeterinary Record, EarlyView.
Abstract Background Allergen‐specific immunotherapy (AIT) is the only aetiological treatment for canine atopic dermatitis (CAD). Pullulan, a polysaccharide with immunomodulatory properties, may enhance AIT outcomes when combined with allergens such as recombinant Dermatophagoides farinae 2 (Der f 2).
Franco Martini   +3 more
wiley   +1 more source

Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis. [PDF]

open access: yesItal J Pediatr
Marseglia GL   +15 more
europepmc   +1 more source

Cell membrane‐coated nanoparticles for dermatological diseases

open access: yesVIEW, EarlyView.
Skin disorders are challenging to treat due to complex barrier functions and limited conventional therapies. Biomimetic cell membrane‐coated nanoparticles (CM‐NPs) offer a superior nanomedicine approach by evading immune detection and enabling precise targeting.
Shuaijun Zou, Baojie Zhang, Yuanjie Zhu
wiley   +1 more source

Home - About - Disclaimer - Privacy